---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-381060"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-09-03T11:50:15+00:00"
generated_at: "2026-09-03T11:55:09.876578+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports positive CLYM116 Phase 1 data: ~29-day half-life, >90% APRIL suppression, Q12W dosing support

## Summary
- CLYM116 half-life ~29 days, 3x longer than sibeprenlimab; >90% free APRIL suppression after single 320 mg dose.
- Single 320 mg dose drove 60-75% suppression of IgA, Gd-IgA1, and IgM, maintained through 12 weeks.
- No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia in 46-subject Phase 1 trial.
- Phase 2 NAVIGATE-2 (800 mg load, 400 mg Q8W/Q12W) ongoing; initial data expected H1 2027; Phase 3 initiation in 2027.
- High-concentration 200 mg/mL formulation enables 400 mg single SC injection; pre-filled syringe complete; autoinjector in development.

## SEC filing metadata
- accession: 0001193125-26-381060
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-09-03T11:50:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/0001193125-26-381060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-381060
- JSON: https://secwatch.observer/filing/0001193125-26-381060.json
- Plain text: https://secwatch.observer/filing/0001193125-26-381060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.